Key result
Pretreatment with unfractionated heparin was associated with a reduction in coronary artery occlusion among patients with STEMI.
Why the study?
Unfractionated heparin is frequently administered before PCI in STEMI, but whether pretreatment prior to catheterisation laboratory arrival affects coronary artery occlusion, mortality, and bleeding remains to be investigated.
Does pretreatment with unfractionated heparin reduce coronary artery occlusion, mortality, and major bleeding in patients with STEMI undergoing PCI?
Cohort (n=41,631)
Yes
Does pretreatment with unfractionated heparin reduce coronary artery occlusion, mortality, and major bleeding in patients with STEMI undergoing PCI?
Pretreatment with unfractionated heparin before PCI in STEMI patients reduces coronary artery occlusion at presentation without increasing major in-hospital bleeding.
Answers are grounded in this paper and cite their sources.
Supports UFH pretreatment hypothesis in STEMI; leaves open randomized confirmation of occlusion reduction.
BACKGROUND: Unfractionated heparin (UFH) is frequently administered before percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). AIMS: The aim of the study was to investigate if pretreatment with UFH prior to arrival at the catheterisation laboratory affects coronary artery occlusion, mortality, and in-hospital major bleeding in patients with STEMI undergoing PCI. METHODS: Patients with a first STEMI event undergoing PCI between 2008 and 2016 were extracted from the Swedish Coronary Angiography and Angioplasty Registry. Risk ratios for UFH pretreatment versus no pretreatment regarding coronary artery occlusion at presentation in the catheterisation laboratory, 30-day mortality, and bleeding were obtained using adjusted Poisson regression models with robust standard errors. Analyses of propensity score (PS)-matched groups were performed to obtain absolute risk differences. RESULTS: In all, 41,631 patients were included, 16,026 (38%) with and 25,605 (62%) without UFH pretreatment. Adjusted risk ratios were 0.89 (95% confidence interval [CI]: 0.87 to 0.90) for coronary artery occlusion, 0.87 (0.77 to 0.99) for mortality, and 1.01 (0.86 to 1.18) for bleeding. In the PS-matched analyses, the absolute risk differences were -0.087 (-0.074 to -0.099) for coronary artery occlusion, -0.011 (-0.017 to -0.0041) for mortality, and 0 (-0.0052 to 0.0052) for bleeding. CONCLUSIONS: Pretreatment with UFH was associated with a reduction in coronary artery occlusion among patients with STEMI, with a number needed to treat (NNT) of 12, without increasing the risk of major in-hospital bleeding. Regarding mortality, a reduction was found with UFH pretreatment, with an NNT of 94, but this effect was not robust over all sensitivity analyses and residual confounding cannot be excluded.
No takes yet. Share an insight, caveat, or question.
Emilsson et al. (2022) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=41,631). Unfractionated heparin (UFH) pretreatment vs. No pretreatment was evaluated on Coronary artery occlusion at presentation in the catheterisation laboratory (RR 0.89, 95% CI 0.87-0.90). Pretreatment with unfractionated heparin was associated with a reduction in coronary artery occlusion among patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: